CrushSCI.com
83Average days
87.5Median days
15Fastest days
180Longest days
1,0992025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

100 days

Formulation-controlled redaporfin cellular-targeted photodynamic therapy sensitizes tumors to PD-1/PD-L1 blockade via immunogenic cell death

Authors
Marta Warszyńska; Lilianna Szyk-Warszyńska; Dominik Barczyk; Paweł Repetowski; Joanna Kuncewicz; Janusz M. DąbrowskiShow moreShow less
Affiliations
Faculty of Chemistry, Jagiellonian University, Kraków 30-387, Poland; Doctoral School of Exact and Natural Sciences, Jagiellonian University, Kraków 30-348, Poland; Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Niezapominajek 8, Krakow 30-239, PolandShow moreShow less
Source PDF DOI Publisher page
180 days

Nicotinate Phosphoribosyltransferase controls aggressiveness, Ca2+ homeostasis, and NAD+-derived Ca2+ mobilizing second messengers in triple-negative breast cancer

Authors
Cecilia Astigiano; Laura Lori; Liliya Euro; Irene Caffa; Moustafa Ghanem; Daniela Verzola; Francesca Ferrera; Daniela Fenoglio; Mario Passalacqua; Alessia Grozio; Maurizio Bruschi; Debora Soncini; Giuseppe Orsomando; Michele Cea; Alessio Nencioni; Santina Bruzzone; Francesco PiacenteShow moreShow less
Affiliations
Department of Experimental Medicine, Biochemistry Section, University of Genoa, Viale Benedetto XV 1, Genoa 16132, Italy; NADMED Ltd, c/o Terkko Health Hub, Haartmaninkatu 4, Bldg 14, Helsinki 00290, Finland; Department of Internal Medicine and Medical Specialties, University of Genoa, Viale Benedetto XV 6, Genoa 16132, Italy; IRCCS Giannina Gaslini Hospital, Molecular Nephrology Laboratory, Via Gaslini 5, Genoa 16147, Italy; Department of Clinical Sciences (DISCO), Section of Biochemistry, Polytechnic University of Marche, Via Ranieri 67, Ancona 60131, Italy; IRCCS Azienda Ospedaliera Metropolitana, Largo R. Benzi 10, Genoa 16132, ItalyShow moreShow less
Source PDF DOI Publisher page
108 days

Selection of novel activators of non-genomic estrogen-like signaling (ANGELS) with promising potential for Alzheimer’s disease

Authors
Szidónia Farkas; Norbert Jeszenői; Tamás Kovács; Adrienn Szabó; Erzsébet Kövesdi; István Horváth; Dóra Zelena; Csaba Hetényi; István ÁbrahámShow moreShow less
Affiliations
Laboratory of Behavioral and Stress Studies, Institute of Physiology, Medical School, University of Pécs, Szigeti Street 12, Pécs 7624, Hungary; Molecular Neuroendocrinology Research Group, Institute of Physiology, Medical School, University of Pécs, Szigeti Street 12, Pécs 7624, Hungary; Centre for Neuroscience, Szentágothai János Research Centre, University of Pécs, Ifjúság Street 20, Pécs 7624, Hungary; Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, 5 Cutcombe Road, London SE5 9RX, UK; Pharmacoinformatics Unit, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti Street 12, Pécs 7624, Hungary; National Laboratory for Drug Research and Development, , Magyar tudósok Street 2, Budapest H-1117, HungaryShow moreShow less
Source PDF DOI Publisher page
57 days

Peripheral GALR2 activation by the metabolically stabilized spexin analog LIT-01-144 produces potent opioid‑independent antinociception

Authors
Yann Berthomé; Glenn-Marie Le Coz; Valérie Utard; Qiuxiang Gu; Rosine Fellmann-Clauss; Nathalie Petit-Demoulière; Raphaëlle Quillet; Claire Gavériaux-Ruff; Sridévi Ramanoudjame; Lucie Estéoulle; Nicolas Humbert; François Daubeuf; Patrick Gizzi; Stéphanie Riché; Xavier Leroy; Dominique Bonnet; Frédéric SimoninShow moreShow less
Affiliations
Laboratoire d’Innovation Thérapeutique, UMR 7200, Centre National de la Recherche Scientifique, Université de Strasbourg, Illkirch, France; Biotechnologie et Signalisation Cellulaire, UMR 7242, Centre National de la Recherche Scientifique, Université de Strasbourg, Illkirch, France; Nantong Laboratory of Development and Diseases, School of Life Sciences, Co-innovation Center of Neuro-regeneration, Nantong University, Nantong, China; Laboratoire de Bioimagerie et Pathologies, Faculté de Pharmacie, UMR 7021, Centre National de la Recherche Scientifique, Université de Strasbourg, Illkirch, France; Plateforme de Chimie Biologique Intégrative de Strasbourg, UAR 3286, Centre National de la Recherche Scientifique, Université de Strasbourg, Illkirch, France; Ankyo, Steinsoultz, FranceShow moreShow less
Source PDF DOI Publisher page
49 days

The selective IGF-1 fusion protein scp776 targets apoptotic cells and promotes recovery of ischemia/reperfusion injured tissues: Engineering and preclinical validation

Authors
Samuel J. Pfaff; Yan Zhang; Walter Olsen; Adam Whitman; Kristopher KuchenbeckerShow moreShow less
Affiliations
Silver Creek Pharmaceuticals, Inc, USAShow moreShow less
Source PDF DOI Publisher page
148 days

Transient ultrastructural remodeling of the open canalicular system and α-granules is associated with endothelial responses after BNT162b2 vaccination in healthy volunteers

Authors
Valentina Carlini; Emilio Trabucchi; Nadia Santo; Norma Lattuada; Stefania Saccucci; Raffaele Allevi; Francesca Rispoli; Barbara Bianchi; Ermanno Longhi; Maria Belen Macas Granizo; Marco D’Anzeo; Cesare Berra; Angelo Naselli; Alberto Settembrini; Elena Tagliabue; Elena Vianello; Elena Dozio; Massimiliano Corsi Romanelli; Antonio E. Pontiroli; Martino Bolognesi; Lucia La SalaShow moreShow less
Affiliations
IRCCS MultiMedica, Via Fantoli 16/15, Milan 20138, Italy; Fondazione MultiMedica ETS, Via Fantoli 16/15, Milan 20138, Italy; UNITECH NOLIMITS – University Technological Platform, University of Milan, Via Golgi 19, Milan 20133, Italy; University of Milan, Dept of Biomedical Sciences and Clinic, Milan 20157, Italy; University of Milan, Dept of Biomedical Sciences for Health, Milan 20133, Italy; AUO delle Marche, SOD Medicina di Laboratorio, Ancona 60100, Italy; Experimental Laboratory for Research on Organ Damage Biomarkers, IRCCS Istituto Auxologico Italiano, Milan Italy; Department of clinical and experimental pathology, IRCCS Istituto Auxologico Italiano, Milan Italy; University of Milan, Dept of Health Science, Milan 20146, ItalyShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does BIOMEDICINE & PHARMACOTHERAPY take to review a manuscript?

As of 2026-11-19, CrushSCI has 16 complete review records for BIOMEDICINE & PHARMACOTHERAPY. The fastest paper went from submission to acceptance in 15 days (Mechanistic insights into Nrf2- and PARP1-mediated radioresistance of glioblastoma stem cells under photon, proton, and carbon ion irradiation: An in vitro study, received 2026-08-18, accepted 2026-09-02); the slowest took 180 days. The average is 83 days and the median is 87.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.